Denali Therapeutics (DNLI) Asset Utilization Ratio (2018 - 2024)
Denali Therapeutics' (DNLI) quarterly Asset Utilization Ratio came in at 0.0 in Q2 2024, down 99.67% year-on-year from 0.25 in Q3 2023, and down 99.62% on a QoQ basis from 0.22 in Q1 2024.
Denali Therapeutics (DNLI) Asset Utilization Ratio (2018 - 2024) Analysis & Trends
Denali Therapeutics (DNLI) has 7 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q2 2024.
- On a quarterly basis, Asset Utilization Ratio fell 99.67% year-over-year to 0.0 in Q2 2024; TTM through Jun 2024 was 0.0, a 99.67% decrease from a year earlier, with the FY2023 full-year figure at 0.25, up 244.71% from the prior year.
- Asset Utilization Ratio for Q2 2024 stood at 0.0, down from 0.22 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for DNLI reached as high as 0.28 in Q4 2023 and fell as low as 0.0 in Q2 2024.
- Historically, Asset Utilization Ratio has averaged 0.14 across 5 years, with a median of 0.12 in 2022.
- Across the five-year window, Asset Utilization Ratio soared 904.98% in 2021 and tumbled 99.67% in 2024, its largest moves.
- Year by year, Asset Utilization Ratio stood at 0.25 in 2020, then tumbled by 78.31% to 0.05 in 2021, then jumped by 49.2% to 0.08 in 2022, then surged by 244.1% to 0.28 in 2023, then sank by 99.7% to 0.0 in 2024.
- Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.0 in Q2 2024, 0.22 in Q1 2024, and 0.28 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Denali Therapeutics | 4.37 Bn | 4.37 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.22 |
| Dec 31, 2023 | 0.28 |
| Sep 30, 2023 | 0.27 |
| Jun 30, 2023 | 0.25 |
| Mar 31, 2023 | 0.07 |
| Dec 31, 2022 | 0.08 |
| Sep 30, 2022 | 0.12 |
| Jun 30, 2022 | 0.11 |
| Mar 31, 2022 | 0.08 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | 0.23 |
| Jun 30, 2021 | 0.23 |
| Mar 31, 2021 | 0.22 |
| Dec 31, 2020 | 0.25 |
| Sep 30, 2020 | 0.02 |
| Jun 30, 2020 | 0.04 |
| Mar 31, 2020 | 0.04 |
| Dec 31, 2019 | 0.05 |
| Sep 30, 2019 | 0.24 |